新西兰 - 英文 - Medsafe (Medicines Safety Authority)

devatis limited - lenalidomide 5mg - capsule - 5 mg - active: lenalidomide 5mg excipient: croscarmellose sodium gelatin lactose magnesium stearate microcrystalline cellulose titanium dioxide - lenalidomide devatis is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation. lenalidomide devatis is indicated for the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide devatis in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

devatis limited - lenalidomide 7.5mg - capsule - 7.5 mg - active: lenalidomide 7.5mg excipient: croscarmellose sodium gelatin iron oxide yellow lactose magnesium stearate microcrystalline cellulose titanium dioxide - lenalidomide devatis is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation. lenalidomide devatis is indicated for the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide devatis in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.

马耳他 - 英文 - Malta Medicines Authority

mercury pharma group limited no. 1 croydon, 12-16 addiscombe road, croydon cr0 0xt, united kingdom - phenindione - tablet - phenindione 50 mg - antithrombotic agents

马耳他 - 英文 - Malta Medicines Authority

mercury pharma group limited no. 1 croydon, 12-16 addiscombe road, croydon cr0 0xt, united kingdom - phenindione - tablet - phenindione 10 mg - antithrombotic agents

美国 - 英文 - NLM (National Library of Medicine)

berrak manufacturing company limited - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - antiseptic uses • hand sanitizer to decrease bacteria on the skin  • recommended for repeated use • for use when soap and water are not available

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

devatis limited - tenoxicam 20mg (+10% overage) - powder for injection - 20 mg - active: tenoxicam 20mg (+10% overage) excipient: ascorbic acid disodium edetate hydrochloric acid mannitol sodium hydroxide trometamol - tenoxicam devatis is indicated in adults for the symptomatic treatment of the following painful inflammatory and degenerative disorders of the musculoskeletal system: - rheumatoid arthritis; - osteoarthritis; - arthrosis; -ankylosing spondylitis; - extra-articular disorders, e.g. tendinitis, bursitis, periarthritis of shoulders (shoulder-hand syndrome) or hips, strains and sprains; - post-operative pain.

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

devatis limited - fingolimod hydrochloride 0.56mg equivalent to fingolimod 0.50 mg - capsule - 0.5 mg - active: fingolimod hydrochloride 0.56mg equivalent to fingolimod 0.50 mg excipient: carmellose calcium gelatin sodium stearyl fumarate - indicated as a disease modifying therapy for the treatment of patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

regional health ltd - arachis oil 0.27%{relative} - oral emulsion - 0.27% w/v - active: arachis oil 0.27%{relative} excipient: amaranth strawberry essence phosphoric acid polysorbate 80 sodium benzoate sodium cyclamate sorbitol water

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - phenindione, quantity: 10 mg - tablet, uncoated - excipient ingredients: maize starch; lactose monohydrate; citric acid; magnesium stearate - indications as at 01 jan 1991 : for the prophylaxis and treatment of thrombosis, embolism and thrombophlebitis. particularly useful in venous thromboembolism.